Transplantation Conditioning Regimens: Can We Say It Better?

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 653-655

  Deeg, H Joachim ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUDARABINE; MELPHALAN;

ACUTE LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; DONOR; EDITORIAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; RECIPIENT; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMPREHENSION; DISEASE-FREE SURVIVAL; GOALS; HUMANS; INFORMED CONSENT; LANGUAGE; MYELOABLATIVE AGONISTS; PUBLISHING; TERMINOLOGY AS TOPIC; TRANSPLANTATION; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 65549146655     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.03.007     Document Type: Editorial

References (23)

1. Thomas E.D., Lochte Jr. H.L., Lu W.C., et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257 (1957) 491-496
2. Burchenal J.H., Oettgen H.F., Holmberg E.A.D., et al. Effect of total body irradiation on the transplantability of mouse leukemias. Cancer Res 20 (1960) 425
3. Barnes D.W.H., Corp M.J., Loutit J.F., et al. Treatment of murine leukaemia with x-rays and homologous bone marrow: preliminary communication. BMJ 2 (1956) 626-627
4. Barnes D.W.H., and Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow II. Br J Haematol 3 (1957) 241-252
5. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300 (1979) 1068-1073
6. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
7. Gale R.P., Horowitz M.M., Ash R.C., et al. Identical twin bone marrow transplants for leukemia. Ann Intern Med 120 (1994) 646-652
8. Fefer A., Cheever M.A., Thomas E.D., et al. Bone marrow transplantation for refractory acute leukemia in 34 patients with identical twins. Blood 57 (1981) 421-430
9. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
10. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 86 (1995) 2041-2050
11. Slavin S., Or R., Nagler A., et al. Allogeneic cell therapy (alloCT) for prevention of relapse in high-risk acute leukemia following allogeneic bone marrow transplantation: control of GVHD by graded increments of donor lymphocyte infusion [abstract]. Blood 88 (1996) 418a
12. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
13. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
14. Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108 (2006) 4288-4290
15. Mohty M., Blaise D., Faucher C., et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 106 (2005) 4407-4411
16. Mohty M., Nagler A., and Killmann N.M. Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink?. Leukemia 20 (2006) 1653-1654
17. Anderlini P., Saliba R., Acholonu S., et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35 (2005) 943-951
18. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
19. Ho A.Y.L., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
20. Deeg H.J., Maris M.B., Scott B.L., et al. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 20 (2006) 1701-1705
21. Ahmed N., Leung K.S., Rosenblatt H., et al. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant 14 (2008) 1298-1304
22. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
23. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10 (2004) 178-185